行情

MOR

MOR

MorphoSys AG
NASDAQ

实时行情|Nasdaq Last Sale

34.40
+0.58
+1.72%
交易中 12:33 12/10 EST
开盘
34.21
昨收
33.82
最高
34.57
最低
34.15
成交量
2.30万
成交额
--
52周最高
34.57
52周最低
22.46
市值
43.63亿
市盈率(TTM)
-41.3810
分时
5日
1月
3月
1年
5年

分析师评级

16位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

MOR 新闻

  • The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares
  • Benzinga.4小时前
  • The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling
  • Benzinga.3天前
  • The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes Dividend
  • Benzinga.4天前
  • Morphosys (MOR) Presents At Piper Jaffray Healthcare Conference - Slideshow
  • Seeking Alpha - Article.4天前

更多

所属板块

生物技术和医学研究
+0.66%
制药与医学研究
+0.69%

热门股票

名称
价格
涨跌幅

MOR 简况

MorphoSys AG develops and commercializes antibodies for therapeutic applications. The Company develops drugs using its own research and development, as well as in cooperation with pharmaceutical and biotechnology partners. The Company's operating segments include Proprietary Development and Partnered Discovery. In the Proprietary Development segment, it develops therapeutic antibodies and peptides in the area of inflammatory disease and oncology. In the Partnered Discovery segment, the Company applies technologies for the research, development and optimization of therapeutic antibodies as drug candidates. The Company develops new treatments for patients suffering from serious diseases. Its technologies include HuCAL, which is a collection fully human antibodies and a system for their optimization; Ylanthia, which is an antibody library in Fab format, and Slonomics, an automated technology for gene synthesis and modification for the generation of gene libraries in a controlled process.
展开

Webull提供MorphoSys AG的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。